Farallon Capital Management’s Pacific Biosciences PACB Stock Holding History

Farallon Capital Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$178K	Hold	135,000	–	–	﹤0.01%	152
2025 Q4	$252K	Hold	135,000	–	–	﹤0.01%	121
2025 Q3	$173K	Hold	135,000	–	–	﹤0.01%	127
2025 Q2	$167K	Hold	135,000	–	–	﹤0.01%	125
2025 Q1	$159K	Hold	135,000	–	–	﹤0.01%	126
2024 Q4	$247K	Hold	135,000	–	–	﹤0.01%	119
2024 Q3	$230K	Hold	135,000	–	–	﹤0.01%	136
2024 Q2	$185K	Sell	135,000 -3,637,452	-96%	-$7.35M	﹤0.01%	142
2024 Q1	$14.1M	Sell	3,772,452 -2,418,918	-39%	-$14.2M	0.06%	88
2023 Q4	$60.7M	Sell	6,191,370 -4,032,750	-39%	-$33M	0.28%	57
2023 Q3	$85.4M	Buy	10,224,120 +1,886,000	+23%	+$21.6M	0.4%	45
2023 Q2	$111M	Buy	8,338,120 +1,983,000	+31%	+$24.1M	0.56%	46
2023 Q1	$73.6M	Buy	6,355,120 +2,350,720	+59%	+$23.4M	0.4%	52
2022 Q4	$32.8M	Buy	+4,004,400	New	+$34.5M	0.19%	71
2022 Q2	–	Sell	-1,631,800	Closed	-$14.8M	–	323
2022 Q1	$14.8M	Sell	1,631,800 -413,688	-20%	-$4.76M	0.07%	115
2021 Q4	$41.9M	Buy	2,045,488 +53,238	+3%	+$1.28M	0.21%	72
2021 Q3	$50.9M	Buy	1,992,250 +1,742,250	+697%	+$51.6M	0.24%	74
2021 Q2	$8.74M	Buy	+250,000	New	+$7.27M	0.04%	140
2021 Q1	–	Sell	-2,100,000	Closed	-$54.5M	–	245
2020 Q4	$54.5M	Sell	2,100,000 -1,963,770	-48%	-$33.4M	0.33%	61
2020 Q3	$40.1M	Buy	4,063,770 +1,063,770	+35%	+$6.12M	0.28%	70
2020 Q2	$10.3M	Hold	3,000,000	–	–	0.08%	102
2020 Q1	$9.18M	Hold	3,000,000	–	–	0.08%	84
2019 Q4	$15.4M	Buy	+3,000,000	New	+$15.2M	0.1%	91

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Farallon Capital Management's PACB Position: Q1 2026 in Review

Farallon Capital Management held its Pacific Biosciences (PACB) position steady in Q1 2026 at 135,000 shares worth $178K. The position accounts for ﹤0.01% of the portfolio, ranked #152.

Farallon Capital Management first reported a position in PACB in Q4 2019 and has held it in 23 quarters since. The position peaked at $111M in Q2 2023. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

Farallon Capital Management held 135,000 shares of Pacific Biosciences worth $178K as of Q1 2026.
Farallon Capital Management left its Pacific Biosciences share count unchanged in Q1 2026.
Pacific Biosciences made up ﹤0.01% of Farallon Capital Management's portfolio in Q1 2026, its #152 holding.
Farallon Capital Management first reported a position in Pacific Biosciences in Q4 2019 and has held it in 23 quarters since.
Farallon Capital Management's Pacific Biosciences position peaked at $111M in Q2 2023.
229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.